December 5, 2025 (WASHINGTON, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the introduction of the Pharmacy Benefit Manager (PBM) Price Transparency and Accountability Act:   “The Partnership to Fight Chronic Disease (PFCD) applauds Senate Finance Committee Chairman Mike Crapo and Ranking Member Ron Wyden for introducing the bipartisan Pharmacy Benefit Manager (PBM) Price Transparency and Accountability Act , which aim

More than half of American adults manage multiple chronic conditions . The prevalence is enough to strain the U.S. healthcare system and challenge patient access to new treatments. To compound the issue, pharmacy benefit managers (PBMs) and others siphon nearly half of every dollar spent on brand-name drugs, driving up costs for patients. Reform for how Americans access drugs is a primary topic in Washington. Of the two trending options on the table, only one puts patients fi

Becoming a new mother is often described as one of life’s most extraordinary experiences. Yet for many women, the period following childbirth is also marked by profound physical, emotional, and systemic challenges. As chronic diseases become increasingly common contributors to maternal complications and mortality, understanding and addressing the broader social determinants of health is essential to addressing the realities, especially those facing Black mothers and their bab

November 26, 2025 (WASHINGTON, D.C.)  The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS) announcement of the “maximum fair prices” for the 15 drugs selected for Medicare price-setting in 2027 under the Inflation Reduction Act (IRA): “Nearly 88% of U.S. adults aged 65+ rely on prescription medicines monthly, with 40% using five or more. When considering how best to improve overal

November 25, 2025 (WASHINGTON, D.C.) The Partnership to Fight Chronic Disease (PFCD) issued the following statement in response to the introduction of the Alzheimer’s Screening and Prevention (ASAP) Act, legislation co-sponsored by Senators Susan Collins (R-ME), Catherine Cortez Masto (D-NV), Shelly Moore Capito (R-WV), Mark Warner (D-VA), and Representatives Vern Buchanan (R-FL) and Paul Tonko (D-NY) to empower Medicare to cover FDA-approved blood-based biomarker tests for